RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Your saved research and appointment questionsView recorded trial and retraction changes
Beta-Propeller Protein-Associated Neurodegeneration: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
A Case of Dental Treatment Under Intravenous Sedation for a Patient With SENDA/BPAN
Kaoru Tomomatsu et al., Anesthesia Progress (1 September 2026)
https://doi.org/10.2344/25-0027
- 2.
Generation of six hiPSC lines from patients with WDR45-related neurodegenerative disease (Beta-propeller Protein-Associated Neurodegeneration, BPAN).
Tournois Johana et al., Stem cell research (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/41962456/
- 3.
Elevated Plasma Phospho-Tau217 in Beta-Propeller Protein-Associated Neurodegeneration.
Lee Jae-Hyeok et al., Movement disorders : official journal of the Movement Disorder Society (12 June 2026)
https://pubmed.ncbi.nlm.nih.gov/42286755/
- 4.
Early Phenotypic Features of Beta-Propeller Protein-Associated Neurodegeneration: Insights From a Korean Series.
Kim Yun Soo et al., Journal of movement disorders (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41367185/
- 5.
A Comprehensive Overview of the Clinical, Electrophysiological, and Neuroimaging Features of BPAN: Insights From a New Case Series.
Susgun Seda et al., Annals of clinical and translational neurology (1 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41097835/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Beta-Propeller Protein-Associated Neurodegeneration
Beta-propeller protein-associated neurodegeneration is a rare genetic brain condition caused by changes in the WDR45 gene. It begins in childhood with developmental delay and seizures, followed in adolescence or adulthood by movement problems such as dystonia and parkinsonism, with iron building up in the brain. Care is supportive, focusing on seizures, movement symptoms and daily function.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Static encephalopathy of childhood with neurodegeneration in adulthood/beta-propeller protein-associated neurodegeneration (SENDA/BPAN) is a rare congenital genetic disorder. The clinical course for this disorder is very specific over time as patients progress from childhood to adulthood. Dysphagia, epilepsy, and intellectual disability were the main complicating factors in this case; however, the patient was planned to undergo intravenous (IV) moderate sedation for her dental care. Midazolam was selected as the first choice to establish a baseline level of sedation due to her epilepsy and intellectual disability. For dysphagia and to minimize excessive movement perioperatively, small 10-mg boluses of propofol were administered to prevent loss of the swallowing reflex, and the depth of sedation was maintained at a Modified Observer’s Assessment of Alertness/Sedation score of approximately 4, which was consistent with moderate sedation. Intraoral water use was kept to a minimum, and any injected water was rapidly suctioned away. We performed IV moderate sedation on a patient with SENDA/BPAN undergoing dental treatment and were able to complete the planned procedure safely using carefully titrated midazolam and propofol.
Common Questions
What is Beta-Propeller Protein-Associated Neurodegeneration?
Beta-propeller protein-associated neurodegeneration is a rare genetic brain condition caused by changes in the WDR45 gene. It begins in childhood with developmental delay and seizures, followed in adolescence or adulthood by movement problems such as dystonia and parkinsonism, with iron building up in the brain. Care is supportive, focusing on seizures, movement symptoms and daily function.
How many clinical trials are available for Beta-Propeller Protein-Associated Neurodegeneration?
RareWays currently indexes 1 clinical trial for Beta-Propeller Protein-Associated Neurodegeneration. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Beta-Propeller Protein-Associated Neurodegeneration come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Beta-Propeller Protein-Associated Neurodegeneration.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.